MX351128B - Polipeptidos manipulados que tienen duracion de accion incrementada. - Google Patents
Polipeptidos manipulados que tienen duracion de accion incrementada.Info
- Publication number
- MX351128B MX351128B MX2013003482A MX2013003482A MX351128B MX 351128 B MX351128 B MX 351128B MX 2013003482 A MX2013003482 A MX 2013003482A MX 2013003482 A MX2013003482 A MX 2013003482A MX 351128 B MX351128 B MX 351128B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- disease
- action
- fatty liver
- engineered polypeptides
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037765 diseases and disorders Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000000736 Amenorrhea Diseases 0.000 abstract 1
- 206010001928 Amenorrhoea Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 102000016267 Leptin Human genes 0.000 abstract 1
- 108010092277 Leptin Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 abstract 1
- 231100000540 amenorrhea Toxicity 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 230000002267 hypothalamic effect Effects 0.000 abstract 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
- 229940039781 leptin Drugs 0.000 abstract 1
- 208000006132 lipodystrophy Diseases 0.000 abstract 1
- 208000011661 metabolic syndrome X Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003442 weekly effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38740210P | 2010-09-28 | 2010-09-28 | |
| US42209110P | 2010-12-10 | 2010-12-10 | |
| PCT/US2011/053786 WO2012050930A2 (en) | 2010-09-28 | 2011-09-28 | Engineered polypeptides having enhanced duration of action |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013003482A MX2013003482A (es) | 2013-10-25 |
| MX351128B true MX351128B (es) | 2017-10-03 |
Family
ID=45938879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003482A MX351128B (es) | 2010-09-28 | 2011-09-28 | Polipeptidos manipulados que tienen duracion de accion incrementada. |
| MX2013003472A MX349054B (es) | 2010-09-28 | 2011-09-28 | Leptinas altamente solubles. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003472A MX349054B (es) | 2010-09-28 | 2011-09-28 | Leptinas altamente solubles. |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20130274182A1 (enExample) |
| EP (4) | EP3241558B1 (enExample) |
| JP (5) | JP2014502252A (enExample) |
| CN (2) | CN103547590B (enExample) |
| BR (3) | BR112013007388B1 (enExample) |
| CA (3) | CA2813038C (enExample) |
| CY (2) | CY1119023T1 (enExample) |
| DK (3) | DK2621515T3 (enExample) |
| EA (2) | EA024507B1 (enExample) |
| ES (3) | ES2873253T3 (enExample) |
| MX (2) | MX351128B (enExample) |
| PL (1) | PL3241558T3 (enExample) |
| PT (2) | PT2621519T (enExample) |
| WO (2) | WO2012050925A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ604805A (en) | 2010-07-09 | 2014-09-26 | Affibody Ab | Polypeptides |
| JP2014502252A (ja) * | 2010-09-28 | 2014-01-30 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 作用持続時間が増した改変ポリペプチド |
| ES2732475T3 (es) * | 2011-07-08 | 2019-11-22 | Aegerion Pharmaceuticals Inc | Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida |
| EP2844269A4 (en) * | 2012-03-28 | 2016-01-06 | Amylin Pharmaceuticals Llc | TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES |
| US10155792B2 (en) | 2012-09-25 | 2018-12-18 | Affibody Ab | Albumin binding polypeptide |
| CN105209054A (zh) | 2013-04-18 | 2015-12-30 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
| JP2016528879A (ja) | 2013-06-17 | 2016-09-23 | アルモ・バイオサイエンシーズ・インコーポレイテッド | タンパク質の同一性および安定性を評価する方法 |
| HK1226308A1 (zh) | 2013-08-30 | 2017-09-29 | Armo Biosciences, Inc. | 使用白细胞介素-10治疗疾病和病症的方法 |
| US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| EP3083675B1 (en) | 2013-12-20 | 2018-03-07 | Affibody AB | Engineered albumin binding polypeptide |
| US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| WO2016034604A1 (en) * | 2014-09-04 | 2016-03-10 | Novo Nordisk A/S | Novel amylin and calcitonin receptor agonist |
| KR20170068553A (ko) | 2014-10-14 | 2017-06-19 | 아르모 바이오사이언시스 인코포레이티드 | 인터류킨-15 조성물 및 이의 용도 |
| JP6675394B2 (ja) | 2014-10-22 | 2020-04-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害の治療のためにインターロイキン−１０を使用する方法 |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| US20160361415A1 (en) | 2015-05-28 | 2016-12-15 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| CN108137653B (zh) | 2015-08-05 | 2021-07-13 | 陕西麦科奥特科技有限公司 | 有抗凝血和抗血小板活性的多靶点化合物及制法和用途 |
| US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| WO2017053391A1 (en) | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| EP3355903A1 (en) | 2015-10-02 | 2018-08-08 | University of Copenhagen | Small molecules blocking histone reader domains |
| PL3509624T3 (pl) | 2016-09-12 | 2024-03-25 | Amryt Pharmaceuticals Inc. | Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie |
| CA3049806A1 (en) * | 2017-01-30 | 2018-08-02 | Alexion Pharmaceuticals, Inc. | Monovalent anti-properdin antibodies and antibody fragments |
| EP3773461A4 (en) * | 2018-04-13 | 2022-02-09 | Massachusetts Institute of Technology | TREATMENTS DESIGNED FOR HAIR REPAIR AND LONG-LASTING COLOR PRESERVATION |
| EP3711772A1 (en) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
| US20240391963A1 (en) * | 2021-09-24 | 2024-11-28 | The Uab Research Foundation | Control of subunit stoichiometry in single-chain msp nanopores |
| WO2025240494A1 (en) * | 2024-05-13 | 2025-11-20 | Lumen Bioscience, Inc. | Leptin compositions and methods of making and using the same to support weight loss and/or maintenance |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4572208A (en) | 1983-06-29 | 1986-02-25 | Utah Medical Products, Inc. | Metabolic gas monitoring apparatus and method |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| FI78231C (fi) | 1984-11-21 | 1989-07-10 | Instrumentarium Oy | Maetanordning foer metaboliska storheter anslutbar till en respirator. |
| US4695463A (en) | 1985-05-24 | 1987-09-22 | Warner-Lambert Company | Delivery system for active ingredients and preparation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| RU2212411C2 (ru) | 1989-10-16 | 2003-09-20 | Эмджен Инк. | Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты) |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| JP3213314B2 (ja) | 1991-04-05 | 2001-10-02 | ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン | 幹細胞因子レセプターに対するモノクローナル抗体 |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6048837A (en) | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5569743A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5563244A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5563245A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| US5594104A (en) | 1995-01-31 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5567803A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5567678A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| AU4766596A (en) | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Ob gene product antibodies |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| WO1996023514A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
| CA2211664A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5569744A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5563243A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5574133A (en) | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
| US5525705A (en) | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
| US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
| EP0736599A3 (en) | 1995-04-03 | 1996-12-11 | Takeda Chemical Industries Ltd | The rat obesity gene, its gene product and its production |
| WO1996031526A1 (en) | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| US5840517A (en) * | 1995-04-26 | 1998-11-24 | Eli Lilly And Company | Process for preparing obesity protein analogs |
| GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
| DE741187T1 (de) | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
| EP0826045A1 (en) | 1995-05-08 | 1998-03-04 | Chiron Corporation | Nucleic acids for treating obesity |
| WO1996037517A1 (en) | 1995-05-26 | 1996-11-28 | Eli Lilly And Company | Rhesus ob protein and dna |
| WO1996040912A1 (en) | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
| US5581005A (en) | 1995-06-16 | 1996-12-03 | The Procter & Gamble Company | Method for manufacturing cobalt catalysts |
| CA2224867A1 (en) | 1995-06-22 | 1997-01-09 | Eli Lilly And Company | Obesity protein intermediates and their preparation and use |
| GB2302559B (en) | 1995-06-23 | 1998-06-03 | Draftex Ind Ltd | Opening arrangements and methods for closure members |
| WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| IL122718A0 (en) | 1995-06-30 | 1998-08-16 | Lilly Co Eli | Methods for treating diabetes |
| ATE259650T1 (de) | 1995-08-17 | 2004-03-15 | Amgen Inc | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen |
| WO1997016550A1 (en) | 1995-11-02 | 1997-05-09 | Bristol-Myers Squibb Company | Polypeptide fragments derived from the obese gene product |
| CA2358862A1 (en) | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| WO1997020933A2 (en) | 1995-12-06 | 1997-06-12 | Schering Corporation | MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| AU2246097A (en) | 1996-01-25 | 1997-08-20 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
| US6013009A (en) | 1996-03-12 | 2000-01-11 | Karkanen; Kip Michael | Walking/running heart rate monitoring system |
| AU2670897A (en) | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
| US6025324A (en) | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
| KR20000016402A (ko) | 1996-06-06 | 2000-03-25 | 피터 기딩스 | 렙틴(ob단백질)의 프레그먼트 |
| US5922678A (en) | 1996-06-28 | 1999-07-13 | Eli Lilly And Company | Methods for treating diabetes |
| JP2001501177A (ja) | 1996-08-30 | 2001-01-30 | アムジエン・インコーポレーテツド | Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法 |
| CA2266585A1 (en) | 1996-09-20 | 1998-03-26 | Hoechst Aktiengesellschaft | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
| WO1998016545A1 (en) | 1996-10-11 | 1998-04-23 | Eli Lilly And Company | Therapeutic proteins |
| WO1998024896A2 (en) | 1996-12-06 | 1998-06-11 | F. Hoffmann-La Roche Ag | Muteins of obese protein |
| CA2275183A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| US6309360B1 (en) | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
| WO1998041222A1 (en) * | 1997-03-20 | 1998-09-24 | Eli Lilly And Company | Obesity protein formulations |
| JP2002504102A (ja) | 1997-06-06 | 2002-02-05 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 糖尿病治療のためのレプチン拮抗物質の使用 |
| EP1001968B1 (en) | 1997-06-13 | 2004-12-22 | Gryphon Therapeutics, Inc. | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution |
| EP1091440B1 (en) | 1998-05-29 | 2010-06-02 | JGC Catalysts and Chemicals Ltd. | Method of manufacturing photoelectric cell |
| JP4199421B2 (ja) | 1998-08-10 | 2008-12-17 | アムジエン・インコーポレーテツド | デキストラン−レプチン結合体、医薬組成物および関連方法 |
| EP1118001A1 (en) | 1998-10-02 | 2001-07-25 | Amgen Inc. | Method to determine a predisposition to leptin treatment |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| EP1658856B1 (en) | 1999-01-14 | 2010-03-17 | Amylin Pharmaceuticals, Inc. | Exendins for glucagon suppression |
| ATE323766T1 (de) | 1999-02-12 | 2006-05-15 | Amgen Inc | Glykosylierte leptinzusammensetzungen und zugehörige verfahren |
| US6475984B2 (en) * | 1999-04-29 | 2002-11-05 | The Nemours Foundation | Administration of leptin |
| TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
| US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
| US6258932B1 (en) | 1999-08-09 | 2001-07-10 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
| CA2388417A1 (en) * | 1999-09-22 | 2001-03-29 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
| US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
| US7057015B1 (en) * | 1999-10-20 | 2006-06-06 | The Salk Institute For Biological Studies | Hormone receptor functional dimers and methods of their use |
| EP1304121A4 (en) | 1999-11-10 | 2004-06-23 | Takeda Chemical Industries Ltd | INHIBITORS OF BODY WEIGHT GAIN |
| JP2001199887A (ja) | 1999-11-10 | 2001-07-24 | Takeda Chem Ind Ltd | 体重増加抑制剤 |
| US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7157564B1 (en) | 2000-04-06 | 2007-01-02 | Affymetrix, Inc. | Tag nucleic acids and probe arrays |
| EP1274720A4 (en) * | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
| US6492117B1 (en) | 2000-07-12 | 2002-12-10 | Gendaq Limited | Zinc finger polypeptides capable of binding DNA quadruplexes |
| US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| US6475158B1 (en) | 2000-10-24 | 2002-11-05 | Korr Medical Technologies, Inc. | Calorimetry systems and methods |
| JP2005506994A (ja) | 2001-10-22 | 2005-03-10 | アムジェン インコーポレイテッド | ヒト脂肪組織萎縮症を処置するためのレプチンの使用および該処置のための素因決定方法 |
| US6899892B2 (en) | 2001-12-19 | 2005-05-31 | Regents Of The University Of Minnesota | Methods to reduce body fat |
| PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| WO2004039832A2 (en) | 2002-10-31 | 2004-05-13 | Albany Medical College | Leptin-related peptides |
| CN1684990A (zh) | 2002-11-01 | 2005-10-19 | 株式会社德山 | 聚合性组合物、其固化体的制造方法以及光学物品 |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| TW200522976A (en) * | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| DE602005021858D1 (de) | 2004-02-11 | 2010-07-29 | Amylin Pharmaceuticals Inc | Peptide der amylin familie, verfahren zu deren herstellung und verwendung |
| US7399744B2 (en) | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| BRPI0518761A2 (pt) | 2004-12-02 | 2008-12-09 | Domantis Ltd | fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente |
| US7898623B2 (en) | 2005-07-04 | 2011-03-01 | Semiconductor Energy Laboratory Co., Ltd. | Display device, electronic device and method of driving display device |
| GB0524788D0 (en) * | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| EP1976873A2 (en) | 2006-01-11 | 2008-10-08 | Brystol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
| JP5252435B2 (ja) | 2006-03-15 | 2013-07-31 | ノボ・ノルデイスク・エー／エス | アミリン誘導体 |
| KR20080106950A (ko) | 2006-03-31 | 2008-12-09 | 아밀린 파마슈티칼스, 인크. | 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제 |
| AU2007267833B2 (en) | 2006-05-26 | 2012-07-26 | Amylin Pharmaceuticals, Llc | Composition and methods for treatment of congestive heart failure |
| WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| CN101113175A (zh) * | 2007-04-28 | 2008-01-30 | 中国科学院西北高原生物研究所 | 鼠兔家族瘦素蛋白及其cDNA序列 |
| JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
| US8937153B2 (en) | 2007-07-31 | 2015-01-20 | Affibody Ab | Compositions, methods and uses |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2195034A2 (en) * | 2007-09-27 | 2010-06-16 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
| KR20100098628A (ko) * | 2007-11-14 | 2010-09-08 | 아밀린 파마슈티칼스, 인크. | 비만 및 비만 관련 질환 및 장애의 치료 방법 |
| NZ602170A (en) * | 2008-02-08 | 2014-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
| US8501686B2 (en) | 2008-06-05 | 2013-08-06 | University Of Michigan | Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects |
| WO2010046357A1 (en) | 2008-10-21 | 2010-04-29 | Novo Nordisk A/S | Amylin derivatives |
| WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
| CN102292346B (zh) | 2009-01-22 | 2015-12-02 | 关键生物科学有限公司 | 肥胖的治疗 |
| CN108530543B (zh) | 2009-02-03 | 2023-06-23 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
| MX348567B (es) * | 2010-06-04 | 2017-06-20 | Tiumbio Co Ltd | Proteina de fusion que tiene actividad de factor vii. |
| NZ604805A (en) | 2010-07-09 | 2014-09-26 | Affibody Ab | Polypeptides |
| JP2014502252A (ja) | 2010-09-28 | 2014-01-30 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 作用持続時間が増した改変ポリペプチド |
| EA201390450A1 (ru) | 2010-09-28 | 2013-07-30 | Амилин Фармасьютикалс, Ллк. | Полипептиды с увеличенной продолжительностью действия |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| ES2732475T3 (es) | 2011-07-08 | 2019-11-22 | Aegerion Pharmaceuticals Inc | Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida |
-
2011
- 2011-09-28 JP JP2013531789A patent/JP2014502252A/ja active Pending
- 2011-09-28 PT PT118330802T patent/PT2621519T/pt unknown
- 2011-09-28 BR BR112013007388-8A patent/BR112013007388B1/pt active IP Right Grant
- 2011-09-28 ES ES17163203T patent/ES2873253T3/es active Active
- 2011-09-28 EP EP17163203.7A patent/EP3241558B1/en active Active
- 2011-09-28 PT PT118330752T patent/PT2621515T/pt unknown
- 2011-09-28 DK DK11833075.2T patent/DK2621515T3/en active
- 2011-09-28 DK DK17163203.7T patent/DK3241558T3/da active
- 2011-09-28 ES ES11833080.2T patent/ES2641869T3/es active Active
- 2011-09-28 EA EA201390474A patent/EA024507B1/ru unknown
- 2011-09-28 ES ES11833075.2T patent/ES2630031T3/es active Active
- 2011-09-28 EP EP17174544.1A patent/EP3305315A1/en not_active Withdrawn
- 2011-09-28 BR BR122021020041-6A patent/BR122021020041B1/pt active IP Right Grant
- 2011-09-28 EP EP11833075.2A patent/EP2621515B1/en active Active
- 2011-09-28 EA EA201390497A patent/EA032917B1/ru unknown
- 2011-09-28 CA CA2813038A patent/CA2813038C/en active Active
- 2011-09-28 CA CA3138758A patent/CA3138758A1/en active Pending
- 2011-09-28 MX MX2013003482A patent/MX351128B/es active IP Right Grant
- 2011-09-28 EP EP11833080.2A patent/EP2621519B1/en active Active
- 2011-09-28 JP JP2013531786A patent/JP6174489B2/ja active Active
- 2011-09-28 WO PCT/US2011/053774 patent/WO2012050925A2/en not_active Ceased
- 2011-09-28 BR BR112013007385-3A patent/BR112013007385B1/pt active IP Right Grant
- 2011-09-28 CN CN201180056939.4A patent/CN103547590B/zh active Active
- 2011-09-28 PL PL17163203T patent/PL3241558T3/pl unknown
- 2011-09-28 CA CA2813087A patent/CA2813087C/en active Active
- 2011-09-28 CN CN201180057153.4A patent/CN103403019B/zh active Active
- 2011-09-28 MX MX2013003472A patent/MX349054B/es active IP Right Grant
- 2011-09-28 DK DK11833080.2T patent/DK2621519T3/en active
- 2011-09-28 WO PCT/US2011/053786 patent/WO2012050930A2/en not_active Ceased
-
2013
- 2013-03-28 US US13/852,671 patent/US20130274182A1/en not_active Abandoned
- 2013-03-28 US US13/852,521 patent/US20130203661A1/en not_active Abandoned
-
2015
- 2015-05-04 US US14/703,523 patent/US10087228B2/en active Active
- 2015-07-15 US US14/800,537 patent/US20160137709A1/en not_active Abandoned
-
2016
- 2016-12-02 JP JP2016235165A patent/JP6608799B2/ja active Active
-
2017
- 2017-02-28 JP JP2017036849A patent/JP6412183B2/ja active Active
- 2017-06-28 CY CY20171100690T patent/CY1119023T1/el unknown
- 2017-09-26 CY CY20171101013T patent/CY1119498T1/el unknown
-
2019
- 2019-10-24 JP JP2019193539A patent/JP2020033366A/ja active Pending
-
2020
- 2020-01-24 US US16/751,538 patent/US11535659B2/en active Active
-
2022
- 2022-10-25 US US18/049,445 patent/US20230115655A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA032917B1 (ru) | Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия | |
| WO2013009539A8 (en) | Engineered polypeptides having enhanced duration of action and reduced immunogenicity | |
| WO2013009545A8 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| MX345245B (es) | Polipeptidos manipulados que tienen duracion de accion incrementada. | |
| MY156316A (en) | Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products | |
| MX2009002893A (es) | Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap). | |
| MX2018005193A (es) | Proteinas de doble funcion y composicion farmaceutica que comprende las mismas. | |
| WO2008021368A3 (en) | Compositions and methods for neuroprotection | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| HK1208155A1 (en) | Transmucosal delivery of engineered polypeptides | |
| WO2007030375A3 (en) | Lysosomal acid lipase therapy for nafld and related diseases | |
| TN2009000124A1 (en) | Injectable depot composition and its process of preparation | |
| JOP20190146A1 (ar) | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد | |
| WO2010011439A3 (en) | Gip-based mixed agonists for treatment of metabolic disorders and obesity | |
| IN2015DN00376A (enExample) | ||
| MX2012008603A (es) | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. | |
| GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
| IN2012DN00827A (enExample) | ||
| WO2005081742A3 (en) | Testosterone oral dosage formulations and associated methods | |
| WO2008043107A3 (en) | Use of tight junction antagonists to treat inflammatory bowel disease | |
| WO2012177653A3 (en) | Targeting the neuromuscular junction for treatment | |
| WO2017123592A8 (en) | Bacteria engineered to treat disorders associated with bile salts | |
| WO2008063768A3 (en) | Compositions and methods for treating metabolic diseases | |
| WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
| TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: AEGERION PHARMACEUTICALS, INC. |
|
| FG | Grant or registration |